Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors, which may lead to slightly greater weight loss in some patients
Ottaviani M, Alestas T, Flori E, Mastrofrancesco A, Zouboulis CC, Picardo M
Many patients are interested in Retatrutide because it may offer enhanced fat-loss support and broader metabolic benefits compared to earlier peptide therapies
Access Alluvis research-grade peptide portfolio, manufactured under controlled conditions with documented purity, batch traceability, and secure handling for non-human R&D applications
But does that mean it actually produces savings